"We're getting a lot of interest in this program... but we don't need to partner. We expect a partner to be flexible and give us the structure that we're looking for. It's hard to time a potential deal or if one will happen, but with the financing, we are in a strong negotiating position."
[Garabedian also confirmed that if Sarepta does a deal, it will more than likely be an ex-U.S. partnership that encompasses the company's entire exon-skipping drug program.]
"We're not taking [eteplirsen] off the table but a potential partner has to buy into the reproducibility of the eteplirsen data for the follow-on exon-skipping programs... We believe eteplirsen significantly de-risks the development of follow-on exon-skipping drugs and makes the entire program highly leverageable. A partner has to buy into that and bring the right economic terms to the table."
On future disclosure of additional eteplirsen data:
"We're right now figuring out how to communicate expectations for 2013. The JP Morgan conference will likely be the venue where I tell investors what to expect from us in 2013. Right now, we're not giving any guidance on if 74-week eteplirsen data will be shared.
[Garabedian will speak to investors at the JP Morgan Healthcare Conference on Weds. Jan. 9.]
On being nominated for the Best Biotech CEO of 2012 award:
"I was humbled, especially since my mentor John Martin [<b>Gilead Sciences'</b> <span class=" TICKERFLAT">(<a href="/quote/GILD.html">GILD</a> - <a href="http://secure2.thestreet.com/cap/prm.do?OID=028198&ticker=GILD">Get Report</a><a class=" arrow" href="/quote/GILD.html"><span class=" tickerChange" id="story_GILD"></span></a>)</span> CEO] is on the list, too. It was a heady experience for me to be mentioned alongside him."
On being told that he's not likely to win the Best Biotech CEO of 2012 award:
"Like they say at the Academy Awards, it's an honor just to be nominated."
-- Reported by Adam Feuerstein in Boston.